{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:48:59Z","timestamp":1791499739619,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":84,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK124301"],"award-info":[{"award-number":["R01DK124301"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005292","name":"Brigham and Women's Hospital","doi-asserted-by":"publisher","award":["Brigham Research Institute Research Excellence Award"],"award-info":[{"award-number":["Brigham Research Institute Research Excellence Award"]}],"id":[{"id":"10.13039\/100005292","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-026-10271-3","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T01:55:49Z","timestamp":1779674149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A heterobifunctional IRAK4-targeting degrader impairs myddosome signaling in acute kidney injury and ameliorates kidney fibrosis"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5431-6447","authenticated-orcid":false,"given":"Marta","family":"Lopez-Marfil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xichi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1949-0762","authenticated-orcid":false,"given":"Diana Ofelia","family":"Lopez-Cantu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Gael","family":"Pelayo-Minero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Ebergenyi-Camarena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelynn","family":"Colunga-Minutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0443-7432","authenticated-orcid":false,"given":"Antonio","family":"Esquivel-Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nello","family":"Mainolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4493-2128","authenticated-orcid":false,"given":"Dario Ruben","family":"Lemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"10271_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.103395","volume":"28","author":"N Guedeney","year":"2022","unstructured":"Guedeney, N., Cornu, M., Schwalen, F., Kieffer, C. & Voisin-Chiret, A. S. PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery. Drug Discov. Today 28, 103395 (2022).","journal-title":"Drug Discov. Today"},{"key":"10271_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M Bekes","year":"2022","unstructured":"Bekes, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181\u2013200 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"10271_CR3","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","volume":"27","author":"DA Nalawansha","year":"2020","unstructured":"Nalawansha, D. A. & Crews, C. M. PROTACs: an emerging therapeutic modality in precision medicine. Cell Chem. Biol. 27, 998\u20131014 (2020).","journal-title":"Cell Chem. Biol."},{"key":"10271_CR4","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","volume":"98","author":"KM Sakamoto","year":"2001","unstructured":"Sakamoto, K. M. et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. USA. 98, 8554\u20138559 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10271_CR5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.molcel.2020.01.010","volume":"77","author":"R Verma","year":"2020","unstructured":"Verma, R., Mohl, D. & Deshaies, R. J. Harnessing the Power of Proteolysis for Targeted Protein Inactivation. Mol. Cell 77, 446\u2013460 (2020).","journal-title":"Mol. Cell"},{"key":"10271_CR6","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/s41587-020-0724-8","volume":"38","author":"A Mullard","year":"2020","unstructured":"Mullard, A. IRAK4 degrader to take on innate immunity. Nat. Biotechnol. 38, 1221\u20131223 (2020).","journal-title":"Nat. Biotechnol."},{"key":"10271_CR7","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1172\/JCI72267","volume":"124","author":"JS Duffield","year":"2014","unstructured":"Duffield, J. S. Cellular and molecular mechanisms in kidney fibrosis. J. Clin. Invest 124, 2299\u20132306 (2014).","journal-title":"J. Clin. Invest"},{"key":"10271_CR8","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2353\/ajpath.2008.080433","volume":"173","author":"SL Lin","year":"2008","unstructured":"Lin, S. L., Kisseleva, T., Brenner, D. A. & Duffield, J. S. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am. J. Pathol. 173, 1617\u20131627 (2008).","journal-title":"Am. J. Pathol."},{"key":"10271_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2353\/ajpath.2010.090517","volume":"176","author":"BD Humphreys","year":"2010","unstructured":"Humphreys, B. D. et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176, 85\u201397 (2010).","journal-title":"Am. J. Pathol."},{"key":"10271_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1172\/JCI87532","volume":"127","author":"IA Leaf","year":"2017","unstructured":"Leaf, I. A. et al. Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury. J. Clin. Invest 127, 321\u2013334 (2017).","journal-title":"J. Clin. Invest"},{"key":"10271_CR11","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1681\/ASN.2017121283","volume":"29","author":"DR Lemos","year":"2018","unstructured":"Lemos, D. R. et al. Interleukin-1beta Activates a MYC-Dependent Metabolic Switch in Kidney Stromal Cells Necessary for Progressive Tubulointerstitial Fibrosis. J. Am. Soc. Nephrol. 29, 1690\u20131705 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"10271_CR12","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1093\/ndt\/gfp214","volume":"24","author":"LK Jones","year":"2009","unstructured":"Jones, L. K. et al. IL-1RI deficiency ameliorates early experimental renal interstitial fibrosis. Nephrol. Dial. Transpl. 24, 3024\u20133032 (2009).","journal-title":"Nephrol. Dial. Transpl."},{"key":"10271_CR13","doi-asserted-by":"publisher","first-page":"15195","DOI":"10.1074\/jbc.RA118.003314","volume":"293","author":"D De Nardo","year":"2018","unstructured":"De Nardo, D. et al. Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a dual role in myddosome formation and Toll-like receptor signaling. J. Biol. Chem. 293, 15195\u201315207 (2018).","journal-title":"J. Biol. Chem."},{"key":"10271_CR14","doi-asserted-by":"publisher","first-page":"10865","DOI":"10.1074\/jbc.M113.544809","volume":"289","author":"L Cushing","year":"2014","unstructured":"Cushing, L. et al. Interleukin 1\/Toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner. J. Biol. Chem. 289, 10865\u201310875 (2014).","journal-title":"J. Biol. Chem."},{"key":"10271_CR15","doi-asserted-by":"publisher","first-page":"15208","DOI":"10.1074\/jbc.RA118.003831","volume":"293","author":"S De","year":"2018","unstructured":"De, S. et al. Mechanism of dysfunction of human variants of the IRAK4 kinase and a role for its kinase activity in interleukin-1 receptor signaling. J. Biol. Chem. 293, 15208\u201315220 (2018).","journal-title":"J. Biol. Chem."},{"key":"10271_CR16","doi-asserted-by":"crossref","unstructured":"A. Slavin (2021) Identification of Highly Potent and Selective Interleukin-1 Receptor Associated Kinase 4 (IRAK4) Degraders for the Treatment of Autoimmune Disease. in European Protein Degradation Congress, September 21st-23rd, 2021.","DOI":"10.1016\/j.jid.2020.03.598"},{"key":"10271_CR17","unstructured":"X. Zheng (2021) Targeted protein degradation in oncology and beyond. in 2nd North American Portein Degradation Congress."},{"key":"10271_CR18","doi-asserted-by":"publisher","first-page":"111.113","DOI":"10.4049\/jimmunol.208.Supp.111.13","volume":"208","author":"SM Skouras","year":"2022","unstructured":"Skouras, S. M. et al. Selective IRAK4 degradation, not kinase inhibition, blocks TLR-activated NF-Kb and p38 Signaling leading to broad cytokine inhibition. J. Immunol. 208, 111.113\u2013111.113 (2022).","journal-title":"J. Immunol."},{"key":"10271_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1172\/JCI75852","volume":"125","author":"IG Gomez","year":"2015","unstructured":"Gomez, I. G. et al. Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J. Clin. Invest 125, 141\u2013156 (2015).","journal-title":"J. Clin. Invest"},{"key":"10271_CR20","doi-asserted-by":"crossref","unstructured":"G. Ligresti. et al. A novel three-dimensional human peritubular microvascular system. JASN 27, (2015).","DOI":"10.1681\/ASN.2015070747"},{"key":"10271_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nprot.2016.170","volume":"12","author":"R Morizane","year":"2017","unstructured":"Morizane, R. & Bonventre, J. V. Generation of nephron progenitor cells and kidney organoids from human pluripotent stem cells. Nat. Protoc. 12, 195\u2013207 (2017).","journal-title":"Nat. Protoc."},{"key":"10271_CR22","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/nbt.3392","volume":"33","author":"R Morizane","year":"2015","unstructured":"Morizane, R. et al. Nephron organoids derived from human pluripotent stem cells model kidney development and injury. Nat. Biotechnol. 33, 1193\u20131200 (2015).","journal-title":"Nat. Biotechnol."},{"key":"10271_CR23","doi-asserted-by":"publisher","first-page":"F552","DOI":"10.1152\/ajprenal.00285.2002","volume":"286","author":"T Ichimura","year":"2004","unstructured":"Ichimura, T., Hung, C. C., Yang, S. A., Stevens, J. L. & Bonventre, J. V. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am. J. Physiol. Ren. Physiol. 286, F552\u2013F563 (2004).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10271_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111225","volume":"40","author":"M Pereira","year":"2022","unstructured":"Pereira, M. et al. The IRAK4 scaffold integrates TLR4-driven TRIF and MYD88 signaling pathways. Cell Rep. 40, 111225 (2022).","journal-title":"Cell Rep."},{"key":"10271_CR25","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/nm.3218","volume":"19","author":"VS LeBleu","year":"2013","unstructured":"LeBleu, V. S. et al. Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 19, 1047\u20131053 (2013).","journal-title":"Nat. Med"},{"key":"10271_CR26","doi-asserted-by":"crossref","unstructured":"D. R. Lemos, J. S. Duffield, Tissue-resident mesenchymal stromal cells: Implications for tissue-specific antifibrotic therapies. Sci. Transl. Med. 10, (2018).","DOI":"10.1126\/scitranslmed.aan5174"},{"key":"10271_CR27","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1021\/acsmedchemlett.0c00255","volume":"11","author":"VR Gummadi","year":"2020","unstructured":"Gummadi, V. R. et al. Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies. ACS Med. Chem. Lett. 11, 2374\u20132381 (2020).","journal-title":"ACS Med. Chem. Lett."},{"key":"10271_CR28","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1084\/jem.20061825","volume":"204","author":"TW Kim","year":"2007","unstructured":"Kim, T. W. et al. A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity. J. Exp. Med. 204, 1025\u20131036 (2007).","journal-title":"J. Exp. Med"},{"key":"10271_CR29","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1084\/jem.20061523","volume":"204","author":"T Kawagoe","year":"2007","unstructured":"Kawagoe, T. et al. Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor-mediated immune responses but not in TCR signaling. J. Exp. Med. 204, 1013\u20131024 (2007).","journal-title":"J. Exp. Med"},{"key":"10271_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nm.2144","volume":"16","author":"L Yang","year":"2010","unstructured":"Yang, L., Besschetnova, T. Y., Brooks, C. R., Shah, J. V. & Bonventre, J. V. Epithelial cell cycle arrest in G2\/M mediates kidney fibrosis after injury. Nat. Med. 16, 535\u2013543 (2010). 531p following 143.","journal-title":"Nat. Med"},{"key":"10271_CR31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/nrneph.2015.3","volume":"11","author":"DA Ferenbach","year":"2015","unstructured":"Ferenbach, D. A. & Bonventre, J. V. Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. Nat. Rev. Nephrol. 11, 264\u2013276 (2015).","journal-title":"Nat. Rev. Nephrol."},{"key":"10271_CR32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature09671","volume":"470","author":"VN Ngo","year":"2011","unstructured":"Ngo, V. N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115\u2013119 (2011).","journal-title":"Nature"},{"key":"10271_CR33","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nrneph.2010.16","volume":"6","author":"A Gluba","year":"2010","unstructured":"Gluba, A. et al. The role of Toll-like receptors in renal diseases. Nat. Rev. Nephrol. 6, 224\u2013235 (2010).","journal-title":"Nat. Rev. Nephrol."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10271-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10271-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10271-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T23:02:53Z","timestamp":1786921373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10271-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10271"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-10271-3","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"9 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: Campbell V., Zheng X., Weiss M., Mainolfi N. and Slavin A. are employees of Kymera Therapeutics. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"1108"}}